Understand the source comparison
Can You Stack LL-37 Other Peptides: Stack Comparison
Before designing a multi-peptide protocol, compare mechanism compatibility and expected outcomes. This comparison evaluates common LL-37 stacks based on mechanism overlap, synergistic potential, and timing requirements. LL-37 + BPC-157 VEGF-mediated angiogenes
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before designing a multi-peptide protocol, compare mechanism compatibility and expected outcomes. This comparison evaluates common LL-37 stacks based on mechanism overlap, synergistic potential, and timing requirements.
- LL-37 + BPC-157
- VEGF-mediated angiogenesis, fibroblast proliferation
- None. BPC-157 works through growth factor pathways
- Administer both simultaneously or LL-37 first, BPC-157 30–60 minutes later
- High. Antimicrobial activity plus tissue repair
- Excellent stack for wound healing models; mechanisms complement without competition
- LL-37 + TB-500
- Actin regulation, cell migration, reduced inflammation
- Minimal. TB-500 targets cytoskeletal dynamics
- TB-500 has longer half-life (days), administer once daily; LL-37 1–2× daily
- High. Infection control plus sustained tissue regeneration
- Strong combination for tissue injury research; TB-500's extended activity window pairs well with LL-37's acute effects
- LL-37 + Ipamorelin
- Growth hormone secretagogue, immune cell proliferation support
- None. Ipamorelin targets ghrelin/growth hormone axis
- LL-37 morning administration, Ipamorelin before sleep
- Moderate. Indirect immune support through GH elevation
- Useful for metabolic and immune function studies; timing separation critical for optimal pulsatility
- LL-37 + Thymosin Alpha-1
- T-cell maturation, dendritic cell activation, IL-2 pathway
- Low overlap. Both modulate immune response through different cell types
- Thymosin Alpha-1 has 2–3 day half-life, administer 2–3× weekly; LL-37 daily
- High. Innate immunity (LL-37) plus adaptive immunity (Thymosin)
- Excellent for comprehensive immune research; covers both immediate antimicrobial response and long-term immune competence
- LL-37 + KPV
- Anti-inflammatory through NF-κB inhibition, reduced cytokine production
- Indirect conflict. KPV's inflammation suppression may reduce LL-37 chemotactic signaling
- Separate by 4–6 hours minimum; LL-37 first for antimicrobial window, KPV later for inflammation control
- Low to Moderate. Timing-dependent, potential cross-inhibition
- Requires careful timing; useful when both antimicrobial activity and inflammation control are needed, but not optimal for acute infection models
- LL-37 + Defensins
- Additional antimicrobial activity through similar membrane disruption
- High. Both are cationic antimicrobial peptides targeting bacterial membranes
- N/A. Simultaneous administration yields no timing benefit
- Low. Redundant mechanism, receptor saturation
- Not recommended; paying for two compounds to perform the same function without proportional benefit increase